Abstract
Natural product extracts have proven to be a rich source of small molecules that potently inhibit the catalytic activity of certain PPP-family ser/thr protein phosphatases. To date, the list of inhibitors includes okadaic acid (produced by marine dinoflagelates, Prorocentrum sp. and Dinophysis sp.), calyculin A, dragmacidins (isolated from marine sponges), microcystins, nodularins (cyanobacteria, Microcystis sp. and Nodularia sp.), tautomycin, tautomycetin, cytostatins, phospholine, leustroducsins, phoslactomycins, fostriecin (soil bacteria, Streptomyces sp.), and cantharidin (blister beetles, approx 1500 species). Many of these compounds share structural similarities, and several have become readily available for research purposes. Here we will review the specificity of available inhibitors and present methods for their use in studying sensitive phosphatases. Common mistakes in the employment of these compounds will also be addressed briefly, notably the widespread misconception that they only inhibit the activity of PP1 and PP2A. Inhibitors of PP2B (calcineurin) will only be mentioned in passing, except to state that, in our hands, cypermethrin, deltamethrin, and fenvalerate, which are sold as potent inhibitors of PP2B, do not inhibit the catalytic activity of PP2B.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bialojan, C. and Takai, A. (1988) Inhibitory effect of a marine-sponge toxin, okadaic acid, on protein phosphatases. Specificity and kinetics. Biochem. J. 256, 283–290.
Honkanen, R. E. and Golden, T. (2002) Regulators of serine/threonine protein phosphatases at the dawn of a clinical era? Curr. Med. Chem. 9, 2055–2075.
Sakoff J. A. and McCluskey, A. (2004) Protein phosphatase inhibition: structure based design. Towards new therapeutic agents. Curr. Pharm. Des. 10, 1139–1159.
Buck, S. B., Hardouin, C., Ichikawa, S., et al. (2003) Fundamental role of the fostriecin unsaturated lactone and implications for selective protein phosphatase inhibition. J. Am. Chem. Soc. 125, 15,694–15,695.
Lewy, D. S., Gauss, C. M., Soenen D. R., and Boger, D. L. (2002) Fostriecin: chemistry and biology. Curr. Med. Chem. 9, 2005–2032.
Ichinose, M., Endo, S., Critz, S. D., Shenolikar, S., and Byrne, J. H. (1990) Microcystin-LR, a potent protein phosphatase inhibitor, prolongs the serotoninand cAMP-induced currents in sensory neurons of Aplysia californica. Brain Res. 533, 137–140.
Fry, D. W., Besserer, J. A., and Boritzki, T. J. (1984) Transport of the antitumor antibiotic Cl-920 into L1210 leukemia cells by the reduced folate carrier system. Cancer Res. 44, 3366–3370.
Favre, B., Turowski P., and Hemmings, B. A. (1997) Differential inhibition and posttranslational modification of protein phosphatase 1 and 2A in MCF7 cells treated with calyculin-A, okadaic acid, and tautomycin. J. Biol. Chem. 272, 13,856–13,863.
Golden, T. A. and Honkanen, R. E. (2003) Regulating the expression of protein phosphatase type 5. Methods Enzymol. 366, 372–930.
Killilea, S. D., Mellgren, R. L., Aylward, J. H., and Lee, E. Y. (1978) Inhibition of phosphorylase phosphatase by polyamines. Biochem. Biophys. Res. Commun. 81, 1040–1046.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press Inc.
About this protocol
Cite this protocol
Swingle, M., Ni, L., Honkanen, R.E. (2007). Small-Molecule Inhibitors of Ser/Thr Protein Phosphatases. In: Moorhead, G. (eds) Protein Phosphatase Protocols. Methods in Molecular Biology, vol 365. Springer, Totowa, NJ. https://doi.org/10.1385/1-59745-267-X:23
Download citation
DOI: https://doi.org/10.1385/1-59745-267-X:23
Publisher Name: Springer, Totowa, NJ
Print ISBN: 978-1-58829-711-2
Online ISBN: 978-1-59745-267-0
eBook Packages: Springer Protocols